What is the latest VIVIMEDLAB stock price?
The latest stored price for VIVIMEDLAB is Rs 5.58 as of 2026-09-18.
gimli
VIVIMEDLAB stock AI analysis
VIVIMEDLAB Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
VIVIMED LABS LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available VIVIMEDLAB price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹5.58
1W return
-9.27%
1M return
+3.33%
3M return
-6.69%
6M return
-14.42%
1Y return
n/a
Market cap
₹46.27 cr
PE
-0.26
PB
-0.22
ROE
+143.63%
ROCE
-65.22%
RSI
36.21
Turnover
₹0.01 cr
Why it can matter in screens
- Momentum: VIVIMEDLAB is below 50DMA, below 200DMA; RSI is 36.21.
- Returns: 1D -1.93%, 1W -9.27%, 1M +3.33%, 3M -6.69%, 1Y n/a.
- Trend levels: 52W high ₹7.21, 52W low ₹4.75, off high -22.61%.
- Liquidity: latest turnover is ₹0.01 cr; volume vs 20D is +0.23%.
- Valuation/profitability: PE -0.26, PB -0.22, ROE +143.63%, ROCE -65.22%.
- Growth: 3Y sales CAGR -27.94%, 3Y profit CAGR n/a.
Quick Answers
Is VIVIMEDLAB above its 50DMA and 200DMA?
VIVIMEDLAB is below 50DMA, below 200DMA. The latest 50DMA is 5.67 and the latest 200DMA is n/a.
What are VIVIMEDLAB PE, ROE and ROCE?
VIVIMEDLAB has PE -0.26, ROE +143.63%, and ROCE -65.22% in Gimli's latest available snapshot.
How has VIVIMEDLAB performed recently?
VIVIMEDLAB has returned +3.33% over 1 month, -6.69% over 3 months, and n/a over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 12.00 cr | -134.53 cr | -147.12 cr | -17.74 |
| 2025-12-31 | 15.99 cr | -10.92 cr | -16.55 cr | -2.00 |
| 2025-09-30 | 20.61 cr | -0.74 cr | -7.30 cr | -0.88 |
| 2025-06-30 | 21.39 cr | 0.10 cr | -5.49 cr | -0.66 |
| 2025-03-31 | 25.61 cr | 0.54 cr | -5.60 cr | -0.68 |
| 2024-12-31 | 36.51 cr | 1.12 cr | -5.97 cr | -0.72 |
| 2024-09-30 | n/a | n/a | n/a | -0.62 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 69.99 cr | -146.11 cr | -176.47 cr | nan |
| 2025-03-31 | 116.27 cr | -9.89 cr | -31.96 cr | -3.85 |
| 2024-03-31 | 149.07 cr | -24.67 cr | -45.45 cr | -5.48 |
| 2023-03-31 | 187.10 cr | -187.24 cr | -328.54 cr | -39.62 |
| 2022-03-31 | 236.57 cr | -8.01 cr | -67.65 cr | -8.16 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 753.48 cr | 1.36 cr | 397.31 cr | -210.55 cr |
| 2025-03-31 | 920.83 cr | 0.71 cr | 376.33 cr | -35.17 cr |
| 2024-03-31 | 950.91 cr | 1.63 cr | 378.79 cr | -5.46 cr |
| 2023-03-31 | 995.05 cr | 3.76 cr | 381.03 cr | 39.42 cr |
| 2022-03-31 | 1,266.02 cr | 7.18 cr | 358.88 cr | 364.29 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 7.70 cr | 6.76 cr | n/a |
| 2025-03-31 | -1.75 cr | -6.28 cr | n/a |
| 2024-03-31 | -23.99 cr | -26.03 cr | n/a |
| 2023-03-31 | 35.32 cr | 30.35 cr | n/a |
| 2022-03-31 | 27.54 cr | 11.13 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +7.57% | +1.64% | +0.00% | +0.00% | +90.67% | +15.18% |
| 2025-12-31 | +7.77% | +1.64% | +0.00% | +0.00% | +90.48% | +14.80% |
| 2025-09-30 | +7.77% | +1.64% | +0.00% | +0.00% | +90.48% | +14.80% |
| 2025-06-30 | +7.77% | +1.64% | +0.00% | +0.00% | +90.48% | +14.80% |
| 2025-03-31 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2024-12-31 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2024-09-30 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2024-06-30 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2024-03-31 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2023-12-31 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2023-09-30 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2023-06-30 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2023-03-31 | +20.94% | +1.64% | +0.00% | +0.00% | +77.30% | +37.06% |
| 2022-12-31 | +20.96% | +1.64% | +0.00% | +0.00% | +77.29% | +37.11% |
| 2022-09-30 | +20.96% | +1.64% | +0.00% | +0.00% | +77.29% | +37.11% |
| 2022-06-30 | +20.96% | +0.12% | +1.64% | n/a | n/a | +37.11% |
| 2022-03-31 | +21.98% | +0.12% | +1.64% | n/a | n/a | +40.02% |
| 2021-12-31 | +28.57% | +0.12% | +1.64% | n/a | n/a | +54.20% |
| 2021-09-30 | +28.57% | +0.12% | +1.85% | n/a | n/a | +54.20% |
| 2021-06-30 | +28.57% | +0.12% | +2.66% | n/a | n/a | +54.20% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze VIVIMED LABS with valuation, momentum and industry peers
- Compare VIVIMEDLAB with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare VIVIMEDLAB with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.